Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Helena M. Earl, MBBS, PhD: Is a Shorter Duration of Trastuzumab Effective in Early-Stage HER2-Positive Breast Cancer?
Posted: Tuesday, October 19, 2021
Helena M. Earl, MBBS, PhD, of the University of Cambridge, offers key insights into the rationale for a study she conducted on whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients with HER2-positive early breast cancer. She also describes how clinicians should interpret the findings.
